# **Stress-induced hyperglycemia predicts poor outcomes in primary ICH patients**

Authors: Kevin Gilotra BS<sup>2</sup>, Jade Basem BS<sup>2</sup>, Melissa Janssen MD<sup>4</sup>, Sujith Swarna BS<sup>2</sup>, Racheed Mani MD<sup>1</sup>, Benny Ren PhD<sup>3</sup>, \*Reza Dashti MD, PhD<sup>1</sup>.

- 1. Department of Neurological Surgery, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- 2. Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA
- 3. Biostatistical Consulting Core, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY
- 4. Department of Neurological Surgery, Loma Linda University, Stony Brook, NY, USA

Abbreviations: ICH – intracerebral hemorrhage, SIH - stress-induced hyperglycemia, DM – diabetes mellitus, mRS - modified Rankin Scale, HTN – hypertension, HLD – hyperlipidemia, CAD - coronary artery disease, CHF - congestive heart failure, AF - atrial fibrillation

\* Corresponding Author: Reza Dashti, MD, PhD, Associate Professor
Department of Neurosurgery, Renaissance School of Medicine at Stony Brook University Cerebrovascular Center, L4-430
Stony Brook, NY 11794-7447
Reza.Dashti@Stonybrookmedicine.edu
Twitter: @RezaDashtiMD
Facebook: Dr Reza Dashti

Short title: Stress-induced hyperglycemia in primary ICH

0

## Abstract

#### Introduction

The current literature suggests hyperglycemia can predict poor outcomes in patients with primary intracerebral hemorrhage (ICH). Chronic hyperglycemia is seen in patients with preexisting diabetes (DM), however, acute hyperglycemia in non-diabetic patients is defined as stressinduced hyperglycemia (SIH). This study explored the influence of hyperglycemia on outcomes of primary ICH patients both in the presence and absence of pre-existing DM.

#### Methods

Data regarding admission glucose, pre-existing DM, inpatient mortality, and modified Rankin scale (mRS) scores at discharge were available for 636 patients admitted to Stony Brook Hospital from January 2011 to December 2022 with a primary diagnosis of ICH. Regression models were used to compare outcomes between patients with admission hyperglycemia and/or pre-existing DM to a control group of normoglycemic and non-diabetic ICH patients.

#### Results

Patients with SIH had higher inpatient mortality rates and worse mRS scores at discharge (p<0.001). An association with higher mortality and worse mRS scores at discharge was also seen in patients with hyperglycemia secondary to DM, although the strength of this association was weaker when compared to patients with SIH.

#### Conclusion

In conclusion, our study's findings suggest that SIH may play a greater role in predicting poor outcomes at discharge rather than a history of poorly controlled DM with chronic hyperglycemia. To develop a more thorough understanding of this topic, prospective studies evaluating the effect of changes in serum glucose during hospital stay on short and long-term outcomes is needed.

1

### **Introduction**

2 Primary intracerebral hemorrhage (ICH) is a devastating condition with a significant rate of mortality and disability (1). ICH forms 10-15% of all strokes, and often requires neurosurgical 3 intervention in addition to comprehensive medical management including strict blood pressure 4 control, and treatment of other underlying medical conditions (2,3). The current literature has 5 6 shown that a variety of metabolic conditions can contribute to worse outcomes in ICH patients 7 (4). Among them, diabetes mellitus (DM) and stress-induced hyperglycemia (SIH) are believed 8 to be the most common metabolic derangements seen in ICH patients (5). SIH is defined as acute 9 glycemic increase in response to significant injury, irrespective of a pre-existing DM diagnosis 10 (5,6). In the current literature, a glucose level > 180 mg/dL in the setting of an acute stressor such as ICH is the typical cut off for defining SIH in non-diabetic patients (7). 11

12 A number of observational studies have demonstrated that SIH is a predictor of mortality, hematoma expansion, and worse functional outcomes amongst primary ICH patients (8–17). 13 Results of INTERACT-2, demonstrated an independent association between both hyperglycemia 14 and DM with 90-day disability and mortality (17). This was further validated in two recent 15 meta-analyses (18,19). When accounting for the presence or absence of DM, majority of studies 16 have shown that SIH predisposes to worse outcomes among ICH patients (14), although others 17 18 found hyperglycemia in diabetic patients also follows this trend when compared with normoglycemic diabetic patients (9,20). Nevertheless, numerous studies to date have found 19 contradictory outcomes regarding significance of admission SIH, its long-term predictive 20 21 potential, and its effect when compared to a diabetic population (21–26). In the present study, our goal was to further explore the association between acute and 22 23 chronic elevated glucose states with early outcomes in primary ICH. We analyzed patients with

2

primary ICH by categorizing them into different groups based on the presence or absence of
previous DM diagnosis and SIH, as defined by admission blood glucose level. We hypothesize
that the presence of SIH on admission will be associated with increased disability and mortality.

### 27 Methods

This study was approved by the Stony Brook University Hospital IRB committee. 28 Medical reports and imaging data was collected retrospectively for all adult patients admitted to 29 Stony Brook University Hospital that presented with intracerebral hemorrhage from January 30 2011 to December 2022. Inclusion criteria was 1) diagnosis of primary ICH, and 2) age over 18 31 years old. Exclusion criteria were 1) ICH secondary to underlying vascular lesions, tumors, or 32 trauma 2) hemorrhagic conversion of ischemic stroke 3) missing diagnosis of DM on admission 33 4) missing blood glucose levels on admission, 5) withdrawal of care or pronouncement of death 34 on admission. 35

Collected data included basic characteristics, demographics, past medical history, preexisting medical conditions, laboratory values on arrival and during admission, radiographic findings, and hematoma locations and volume. Modified Rankin Scale (mRS) and Intracerebral Hemorrhage (ICH) scores on admission and discharge were collected as well as social factors such as Do Not Resuscitate/Intubate (DNR/DNI) status and location of discharge.

Patients were categorized into four groups based on previous diagnosis of DM and the
presence of admission hyperglycemia. SIH was defined as admission glucose >180 mg/dL in
non-diabetic patients as in line with previous literature that has used cut-offs ranging from 140200 for diagnostic purposes (7). *Figure 1* highlights the categorization of patients. The four
groups were defined as Group A – (SIH): blood glucose levels on admission above 180 mg/dL

3

46	without history of DM, Group B – diabetic hyperglycemia (DH): blood glucose levels on
47	admission above 180 mg/dL on admission with previous history of DM, Group C (DM only) –
48	normoglycemia on admission with a history of DM, and Group D (control) – normoglycemia on
49	admission without history of DM. As previously described in the CHEERY study with a similar
50	methodology, (14) the purpose of organizing the groups this way was to determine whether poor
51	outcomes amongst diabetic patients occurred independently of SIH and similarly, if poor
52	outcomes amongst patients with admission hyperglycemia occurred due to SIH or hyperglycemia
53	from underlying DM. For groups A and B, we homogenized our cut-off for both SIH and
54	admission hyperglycemia at a cut-off of 180 mg/dL to compare diabetic patients and non-diabetic
55	patients more effectively with hyperglycemia on admission.
56	The two primary endpoints were inpatient mortality and level of disability at discharge
57	which was defined by two groups of mRS 0-2 and mRS 3-6 at discharge, with each being
58	considered as "favorable" and "unfavorable" outcome respectively (13). Discharge status to
59	home versus acute care facility or hospice and DNR/DNI status were considered as additional
60	secondary outcome measurements. Figure 2 outlines which binary outcome was considered
61	favorable vs. unfavorable.
62	For the multivariate regression analysis, Groups A, B, and C were compared to reference
63	Group D as these patients had neither SIH, admission hyperglycemia or DM. We controlled for
64	age, sex and ethnicity for each regression analysis. We used the statistical software R for our
65	analysis of dichotomous and ordinal outcomes. Ordinal logistic regression and standard logistic
66	allow us to compare odds ratios for group effects on the same scale (27–29).

67

4

### 68 **Results**

1006 consecutive patients presented with ICH during this period. Based on exclusion criteria 636 69 70 patients with primary ICH, and available glucose levels were included in this retrospective analysis. *Table 1* highlights the characteristics of the four groups of patients in this study. 71 Patients were stratified into one of four groups (Figure 1): non-diabetic patients with SIH (Group 72 A, n=42), diabetic patients with SIH (Group B, n=70), diabetic patients without SIH (Group C, 73 74 N=101), and non-diabetic patients without SIH (Group D, N=423). Inpatient mortality rate amongst the entire sample was 16.6%. 6.6% of total patients had SIH (mean age = 74, 75 male/female = 25/17), of which 45.2% expired in-hospital. 17.6% of total patients had 76 77 hyperglycemia of which 36.6% expired in-hospital. 22.9% of total patients had DM of which 21.1% expired in-hospital. When looking within each group, patients with SIH/hyperglycemia 78 79 with and without DM had nearly double the percentage of mortality compared to the corresponding groups without SIH. Discharge to rehab, acute care facility, or other location was 80 higher than discharge home or with home with hospice for all groups. Group A patients were 81 primarily male (59.5%) while the majority of Group B (and Group C patients were female 82 (57.1% and 58.4%, respectively). 83

We generated logistic and ordinal logistic regression models that controlled for a variety of pre-existing comorbidities based on what was deemed important in prior studies (14, 27–29), age, sex and ethnicity. Ordinal outcomes were reordered to maintain the same direction of effect for adverse outcomes as standard logistic regression. In our analysis, positive coefficients correspond with an increased probability of adverse clinical outcomes. These included hypertension (HTN), hyperlipidemia (HLD), coronary artery disease (CAD), congestive heart

5

failure (CHF), obesity, prior primary ICH, atrial fibrillation (AF), hematoma location (B and C), 90 malignancy and the presence of anticoagulation or antiplatelet therapy. Table 2 highlights the 91 multivariate logistic and ordinal logistic regression coefficients for Groups A-C to assess their 92 correlation with the primary outcomes (excluding patients without DM and without SIH). 93 A statistically significant association was seen between inpatient mortality and both Group A 94 95 (p<0.0001) and Group B patients (p=0.0003) but not in the other two groups. Discharge to hospice, acute care facilities and rehabilitation centres was observed significantly more amongst 96 97 both Group A (p=0.011) and Group B patients (p=0.0016). There was no association between initial hematoma volume and admission glucose, or a history of DM seen across the four groups. 98 When comparing Group A and B, the odds ratios for Group A were higher than what was seen 99 for Group B regarding all primary outcomes including inpatient mortality, unfavorable discharge 100 101 mRS, and unfavorable discharge status. Group A was noted to have higher mRS scores on 102 admission (p < 0.0001) but no association was found with hematoma volume or ICH scores. The 103 remainder of the groups demonstrated no statistically significant association with either hematoma volumes, ICH scores or mRS scores for their presentation on admission. Notably, ORs 104 were also higher for Group A when assessing severity of presentation in comparison to Group B, 105 106 as demonstrated by worse mRS scores and ICH scores at admission.

### **Discussion**

Admission hyperglycemia and SIH are both associated with worse outcomes in primary ICH patients (17,19). Furthermore, SIH is thought to be a compensatory response to an acute stressor, such as ICH, in patients without previous diagnosis of diabetes (6). It has been hypothesized that the catecholamine surge in conjunction with many other hormones, particularly cortisol, are

6

responsible for mediating this process by inhibiting glucose uptake into skeletal muscle and increasing gluconeogenesis in the liver (6). Although the purpose of this acute adaptation is to provide the body with more energy in the setting of a physical stressor, acute hyperglycemia can simultaneously cause significant damage to neuronal tissue through oxidative stress and inflammation (6). Other proposed mechanisms for how hyperglycemia leads to neuronal damage include inhibition of cellular proteins such as aquaporin-4 and kallikrein (30,31).

The European Stroke Organization recommends controlling serum glucose through 118 intravenous insulin infusion in a manner that mimics normal physiology while avoiding boluses 119 120 with high-dose subcutaneous insulin (32). Despite this recommendation, however, some studies have found that tight glycemic control does not necessarily lead to a major improvement in either 121 short-term or long-term outcomes (33,34). In an RCT of 78 patients with SAH, intensive insulin 122 123 therapy did not lead to significantly improved outcomes (33). A larger meta-analysis of 1248 neurocritical care patients further demonstrated that intensive insulin therapy raises the risk of 124 125 hypoglycemia and offers minimal mortality benefit (34). Glycemic control in the inpatient setting is often done on a case-by-case basis where the patient's pre-existing medical history, baseline 126 glucose levels and overall clinical status is collectively taken into consideration. The lack of 127 128 consensus on how glucose should be monitored in these patients may be attributed to few studies comparing outcomes amongst non-diabetic and diabetic ICH patients with SIH. 129

To address this management issue, the question now becomes whether poor outcomes in ICH patients are due to the deleterious effects of pre-existing chronic hyperglycemia as seen in poorly controlled diabetics or because of the inflammation, edema and hematoma expansion that occurs in the setting of SIH. While both factors are likely to play a role in these outcomes, the current literature pertaining to this topic is both limited and somewhat conflicting. Godoy et al.'s

7

135	study of 510 ICH patients demonstrated no significant differences in mortality when comparing
136	those with admission glucose > 160 mg/dL to those with admission glucose < 160 mg/dL (23).
137	On the contrary, Kimura et al. demonstrated that an admission glucose $> 150 \text{ mg/dL}$
138	independently predicted inpatient mortality in a sample of 100 ICH patients (8). Meanwhile,
139	another study highlighted that hyperglycemia that persists throughout a hospital stay is
140	associated with higher mortality rates when compared to transient hyperglycemia or
141	normoglycemia (24). The INTERACT-2 study showed that both hyperglycemia and DM were
142	independently associated with long-term disability at 90 day follow-up and higher mortality rates
143	(17).
144	Few studies have comprehensively compared outcomes between ICH patients with
145	normoglycemia to ICH patients with elevated glucose levels due to SIH or hyperglycemia in the
146	setting of DM. Results from this study showed that patients with SIH (Group A) had a
147	significantly higher risk of unfavorable outcomes when compared to normoglycemic and non-
148	diabetic patients (Group D). Regression coefficients from Table 2 show that Group A patients
149	had a stronger association with inpatient mortality, unfavorable discharge status, and a higher
150	likelihood of being made DNR/DNI compared to all other groups. Both Group A and Group B
151	patients with admission hyperglycemia and DM were significantly more likely to present with
152	higher mRS scores and ICH scores on admission, indicating more severe presentations. Unlike
153	previous studies which set arbitrary cut-offs of hyperglycemia ranging from 140-200 mg/dL, we
154	used the same cut-off of 180 mg/dL to define hyperglycemia in non-diabetic patients, which was
155	deemed as SIH (Group A), and diabetic patients (Group B). Even after homogenizing the cut-off
156	value, our results yielded regression coefficients that demonstrated a much stronger association
157	with unfavorable outcomes amongst ICH patients with SIH (Group A) when compared to

8

regression coefficients for ICH patients with DM and admission hyperglycemia (Group B). In 158 other words, while the combination of DM and admission hyperglycemia was associated with 159 worse outcomes amongst Group B patients, the strength of this association was weaker when 160 compared to the presence of SIH alone in Group A patients. This may support the notion that 161 SIH has a more prominent effect on poor outcomes in ICH patients than hyperglycemia due to 162 163 DM. Importantly, our study's findings are very similar to Sun et al.'s study which demonstrated that admission glucose was predictive of poor outcomes at 3-months of follow-up in non-diabetic 164 165 patients, but admission glucose was not quite predictive in diabetic patients (20). 166 While poor outcomes associated with SIH may be due to rapid maladaptive pathophysiological changes, chronic hyperglycemia in the setting of DM can also affect 167 outcomes through a more insidious process. Atherosclerotic changes to cerebral 168 169 microvasculature and endothelial damage can predispose to vessel rupture and subsequently 170 higher volumes of bleeding (14). Perihematomal cell necrosis, cerebral edema and concomitant 171 hematoma expansion in diabetic ICH patients may all serve as plausible mechanisms for why chronic hyperglycemia is associated with poor outcomes (35,36). Additionally, poor outpatient 172 glycemic control may further propagate worse outcomes in diabetic patients (37). Despite this 173 174 evidence, our study's results showed no significant associations between unfavorable outcomes 175 amongst patients with a history of DM who had normoglycemia on admission (Group C). This 176 trend may have occurred because Group C patients had relatively well-controlled diabetes, as 177 demonstrated by their normoglycemia on admission. It is important to note that in many prior studies, ICH patients with DM are often compared to those without DM, with little consideration 178 179 given to serum glucose levels. By comprehensively evaluating serum glucose levels through four 180 individual strata in our study, our results may further support the notion that the deleterious

9

pathophysiology of SIH has a greater effect on outcomes amongst ICH patients than the chronicvasculopathy that occurs due to DM.

183 Notable strengths of this study include a relatively large sample size amongst each of the 184 individual four strata. This allowed us to perform a complex regression model that compared 185 four groups in an analysis that has rarely been done in the current literature (14). In our 186 regression analysis, we controlled for the presence of multiple CVD risk factors which may have 187 served as confounders of poor outcomes in ICH patients in previous studies.

### **188** Limitations

Our study has a few limitations. Firstly, the retrospective nature of the study limits our 189 ability to determine a direct cause-and-effect relationship between hyperglycemia and poor 190 outcomes. Additionally, this was a single-center analysis subject to institution-dependent biases 191 and it did not assess long-term follow-up after patients had been discharged from the inpatient 192 193 setting. Another limitation was that pre-admission blood glucose levels and baseline HBA1C 194 values were not available, thus making it difficult to discern the patient's baseline glycemic 195 control and potential chronic hyperglycemia prior to admission. Similarly, we could not obtain 196 the duration of pre-existing DM in patient-years or distinguish between type one or type two DM. Finally regarding our statistical analysis, because ordinal regression is widely used in the 197 198 literature (38), we leave further extensions beyond standard ordinal regression to future work.

# **Conclusion**

Results of this study demonstrate that SIH predicts poor outcomes in ICH patients
regardless of their history of DM, although patients without DM had a stronger association with

10

202	poor outcomes. Glycemic control for non-diabetic patients with SIH greatly differs from those
203	with DM and pre-existing chronic hyperglycemia. SIH patients are given insulin boluses to keep
204	their glucose levels below 180 mg/dL while diabetic patients need additional insulin on top of
205	their basal-bolus regimen and regular diabetic medications. To develop a thorough understanding
206	of the effects of DM and SIH in the role of ICH, larger randomized controlled trials evaluating
207	changes in serum glucose during hospital stay in response to different forms of medical
208	management, and then evaluating long-term outcomes, are needed.

# 209 Acknowledgements

210 We would like to acknowledge all members of the Dashti Lab who contributed to the research

211 process for this study.

# 212 Sources of Funding

213 None.

# 214 **Disclosures**

215	None.		
216			
217			
218			
219			
220			
221			

11

# 222 **References**

- Van Asch CJ, Luitse MJ, Rinkel GJ, Van Der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and
   functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a
   systematic review and meta-analysis. Lancet Neurol. 2010 Feb;9(2):167–76.
- Stein M, Misselwitz B, Hamann GF, Scharbrodt W, Schummer DI, Oertel MF. Intracerebral Hemorrhage in the Very Old: Future Demographic Trends of an Aging Population. Stroke. 2012 Apr;43(4):1126–8.
- Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-Year Survival of Intracerebral Hemorrhage in a Population-Based Registry. Stroke. 2009 Feb;40(2):394–9.
- 4. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and
  Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation
  [Internet]. 2023 Feb 21 [cited 2024 Apr 19];147(8). Available from:
- 234 https://www.ahajournals.org/doi/10.1161/CIR.000000000001123
- 5. McCowen KC, Malhotra A, Bistrian BR. STRESS-INDUCED HYPERGLYCEMIA.
- 6. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. The Lancet. 2009
  May;373(9677):1798–807.
- 7. Vedantam D, Poman DS, Motwani L, Asif N, Patel A, Anne KK. Stress-Induced Hyperglycemia:
  Consequences and Management. Cureus [Internet]. 2022 Jul 10 [cited 2024 Apr 19]; Available from:
  https://www.cureus.com/articles/100945-stress-induced-hyperglycemia-consequences-andmanagement
- 8. Kimura K, Iguchi Y, Inoue T, Shibazaki K, Matsumoto N, Kobayashi K, et al. Hyperglycemia
  independently increases the risk of early death in acute spontaneous intracerebral hemorrhage. J
  Neurol Sci. 2007 Apr;255(1–2):90–4.
- 9. Stöllberger C, Exner I, Finsterer J, Slany J, Steger C. Stroke in diabetic and non-diabetic patients:
  Course and prognostic value of admission serum glucose. Ann Med. 2005 Jan;37(5):357–64.
- Fogelholm R. Admission blood glucose and short term survival in primary intracerebral
  haemorrhage: a population based study. J Neurol Neurosurg Psychiatry. 2005 Mar 1;76(3):349–53.
- Gong Y, Wang Y, Chen D, Teng Y, Xu F, Yang P. Predictive value of hyperglycemia on prognosis
   in spontaneous intracerebral hemorrhage patients. Heliyon. 2023 Mar;9(3):e14290.
- 12. Chu H, Huang C, Tang Y, Dong Q, Guo Q. The stress hyperglycemia ratio predicts early
   hematoma expansion and poor outcomes in patients with spontaneous intracerebral hemorrhage. Ther
   Adv Neurol Disord. 2022 Jan;15:175628642110706.
- Li S, Wang Y, Wang W, Zhang Q, Wang A, Zhao X. Stress hyperglycemia is predictive of clinical
   outcomes in patients with spontaneous intracerebral hemorrhage. BMC Neurol. 2022 Dec;22(1):236.

12

256 257 258	14. Chen S, Wan Y, Guo H, Shen J, Li M, Xia Y, et al. Diabetic and STRESS-INDUCED hyperglycemia in spontaneous intracerebral hemorrhage: A multicenter prospective cohort (CHEERY) study. CNS Neurosci Ther. 2023 Apr;29(4):979–87.
259 260 261	15. Zhou Y, Luo Z, Yu M, Zhan C, Xu H, Lin R, et al. Acute Phase Blood Glucose Levels and Functional Outcomes in Patients with Spontaneous Intracerebral Hemorrhage. Neuropsychiatr Dis Treat. 2023 Dec;Volume 19:2697–707.
262 263 264	16. Li G, Wang S, Xiong Y, Gu H, Jiang Y, Yang X, et al. Higher fasting blood glucose was associated with worse in-hospital clinical outcomes in patients with primary intracerebral hemorrhage: From a large-scale nationwide longitudinal registry. CNS Neurosci Ther. 2022 Dec;28(12):2260–7.
265 266 267	17. Saxena A, Anderson CS, Wang X, Sato S, Arima H, Chan E, et al. Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage: The INTERACT2 Study. Stroke. 2016 Mar;47(3):682–8.
268 269 270	<ol> <li>Zheng J, Yu Z, Ma L, Guo R, Lin S, You C, et al. Association Between Blood Glucose and Functional Outcome in Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Jun;114:e756–65.</li> </ol>
271 272 273	19. Guo X, Li H, Zhang Z, Li S, Zhang L, Zhang J, et al. Hyperglycemia and Mortality Risk in Patients with Primary Intracerebral Hemorrhage: A Meta-Analysis. Mol Neurobiol. 2016 May;53(4):2269–75.
274 275	20. Sun S, Pan Y, Zhao X, Liu L, Li H, He Y, et al. Prognostic Value of Admission Blood Glucose in Diabetic and Non-diabetic Patients with Intracerebral Hemorrhage. Sci Rep. 2016 Aug 26;6(1):32342.
276 277 278	<ol> <li>Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview. Stroke. 2001 Oct;32(10):2426– 32.</li> </ol>
279 280 281	22. Stead LG, Jain A, Bellolio MF, Odufuye A, Gilmore RM, Rabinstein A, et al. Emergency Department Hyperglycemia as a Predictor of Early Mortality and Worse Functional Outcome after Intracerebral Hemorrhage. Neurocrit Care. 2010 Aug;13(1):67–74.
282 283 284	<ol> <li>Godoy DA, Piñero GR, Svampa S, Papa F, Di Napoli M. Hyperglycemia and Short-term Outcome in Patients with Spontaneous Intracerebral Hemorrhage. Neurocrit Care. 2008 Oct;9(2):217– 29.</li> </ol>
285 286 287	24. Wu TY, Putaala J, Sharma G, Strbian D, Tatlisumak T, Davis SM, et al. Persistent Hyperglycemia Is Associated With Increased Mortality After Intracerebral Hemorrhage. J Am Heart Assoc. 2017 Aug 2;6(8):e005760.
288 289	25. Zhao Y, Yang J, Zhao H, Ding Y, Zhou J, Zhang Y. The association between hyperglycemia and the prognosis of acute spontaneous intracerebral hemorrhage. Neurol Res. 2017 Feb 1;39(2):152–7.
290 291 292	26. Kang K, Lu J, Ju Y, Wang W, Shen Y, Wang A, et al. Association of pre- and post-stroke glycemic status with clinical outcome in spontaneous intracerebral hemorrhage. Sci Rep. 2019 Dec 13;9(1):19054.

13

293 294 295	27. Qureshi AI, Huang W, Lobanova I, Chandrasekaran PN, Hanley DF, Hsu CY, et al. Effect of Moderate and Severe Persistent Hyperglycemia on Outcomes in Patients With Intracerebral Hemorrhage. Stroke. 2022 Apr;53(4):1226–34.
296	<ol> <li>Yee TW. The VGAM package for negative binomial regression. Aust N Z J Stat. 2020</li></ol>
297	Mar;62(1):116–31.
298 299 300	29. Yee TW, Stoklosa J, Huggins RM. The VGAM Package for Capture-Recapture Data Using the Conditional Likelihood. J Stat Softw [Internet]. 2015 [cited 2024 Apr 19];65(5). Available from: http://www.jstatsoft.org/v65/i05/
301	30. Chiu CD, Chen CCV, Shen CC, Chin LT, Ma HI, Chuang HY, et al. Hyperglycemia Exacerbates
302	Intracerebral Hemorrhage via the Downregulation of Aquaporin-4: Temporal Assessment With
303	Magnetic Resonance Imaging. Stroke. 2013 Jun;44(6):1682–9.
304 305	31. Liu J, Gao BB, Clermont AC, Blair P, Chilcote TJ, Sinha S, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011 Feb;17(2):206–10.
306	32. Fuentes B, Ntaios G, Putaala J, Thomas B, Turc G, Díez-Tejedor E, et al. European Stroke
307	Organisation (ESO) guidelines on glycaemia management in acute stroke. Eur Stroke J. 2018
308	Mar;3(1):5–21.
309	33. Bilotta F, Spinelli A, Giovannini F, Doronzio A, Delfini R, Rosa G. The Effect of Intensive
310	Insulin Therapy on Infection Rate, Vasospasm, Neurologic Outcome, and Mortality in Neurointensive
311	Care Unit After Intracranial Aneurysm Clipping in Patients With Acute Subarachnoid Hemorrhage: A
312	Randomized Prospective Pilot Trial. J Neurosurg Anesthesiol. 2007 Jul;19(3):156–60.
313 314	34. Kramer AH, Roberts DJ, Zygun DA. Optimal glycemic control in neurocritical care patients: a systematic review and meta-analysis. Crit Care. 2012;16(5):R203.
315	<ol> <li>Song EC, Chu K, Jeong SW, Jung KH, Kim SH, Kim M, et al. Hyperglycemia Exacerbates Brain</li></ol>
316	Edema and Perihematomal Cell Death After Intracerebral Hemorrhage. Stroke. 2003 Sep;34(9):2215–
317	20.
318	<ol> <li>Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, et al. Determinants of</li></ol>
319	Intracerebral Hemorrhage Growth: An Exploratory Analysis. Stroke. 2007 Mar;38(3):1072–5.
320	37. Saliba W, Barnett-Griness O, Gronich N, Molad J, Naftali J, Rennert G, et al. Association of
321	Diabetes and Glycated Hemoglobin With the Risk of Intracerebral Hemorrhage: A Population-Based
322	Cohort Study. Diabetes Care. 2019 Apr 1;42(4):682–8.
323	38. Ganesh A, Luengo-Fernandez R, Wharton RM, Rothwell PM. Ordinal vs dichotomous analyses
324	of modified Rankin Scale, 5-year outcome, and cost of stroke. Neurology [Internet]. 2018 Nov 20
325	[cited 2024 May 27];91(21). Available from:
326	https://www.neurology.org/doi/10.1212/WNL.000000000006554


327

328

14


# **Appendices**

#### 330



#### 331

- **Figure 1:** Groups A through D for study design with presence or absence of hyperglycemia on admission
- and DM indicated. \*SIH stress-induced hyperglycemia, DH diabetic hyperglycemia, NG –
   normoglycemia, CL control



335

- **Figure 2:** Binary classification of primary outcomes being compared between two groups. \*Patients who
- 337 were already DNR/DNI before admission were excluded from this group.

1	5
_	-

Demographic Information (N=636) <sup>a</sup>	Group A - SIH (N=42)	Group B – Admission hyperglycemia and history of DM (N=70)	Group C – History of DM and normoglycemia on admission (N=101)	Group D – Normoglycemia on admission without history of DM (N=423)
Median Age	74	71	75	74
Sex				
Female	17 (40.5%)	40 (57.1%)	59 (58.4%)	214 (50.6%)
Male	25 (59.5%)	30 (42.9%)	42 (41.6%)	209 (49.4%)
Race/Ethnicity			· · ·	· · · · ·
African American	0 (0%)	8 (11.4%)	10 (9.9%)	33 (7.8%)
Asian	0 (0%)	1 (1.4%)	7 (6.9%)	6 (1.4%)
Hispanic	0 (0%)	3 (4.3%)	3 (3.0%)	7 (1.7%)
White	42 (100%)	58 (82.9%)	81 (80.2%)	377 (89.1%)
Clinical Outcomes (N=636) Inpatient Mortality	19 (45.2%)	22 (31.4%)	14 (13.9%)	51 (12.1%)
Discharged Home Discharged to Rehab or Acute Care Facility or	1 (2.4%) 29 (69.0%)	4 (5.7%) 43 (61.4%)	20 (19.8%) 67 (66.3%)	103 (24.3%)           270 (63.8%)
Home with Hospice or other mRS discharge	0 (0.0%)	7 (10.0%)	20 (19.8%)	08 (22 29/)
0-2	, , , , , , , , , , , , , , , , , , ,		20 (19.870)	98 (23.2%)
mRS discharge 3 – 6	42 (100%)	63 (90.0%)	81 (80.2%)	323 (76.4%)
DNR/DNI before admission or within 24 hours	17 (40.5%)	9 (12.9%)	20 (19.8%)	81 (19.1%)
DNR/DNI after 24 hours	8 (19.0%)	17 (24.3%)	11 (10.9%)	42 (9.9%)

"Table 1 highlights demographic characteristics and clinical outcomes for patients in all four groups.

Outcome	Group A – SIH (95% CI)	P-value	Group B – History of DM and normoglyce mia on admission (95% CI)	P-value	Group C – Normoglycem ia on admission without history of DM (95% CI)	P-value
Inpatient Mortality	1.730 (0.995, 2.465)	<0.001	1.169 (0.537, 1.801)	< 0.001	-0.110 (-0.801, 0.580)	0.754
Unfavorable mRS discharge (3-6)	N/A*	N/A*	1.070 (0.171, 1.969)	0.020	0.221 (-0.451, 0.893)	0.520
Unfavorable DNR/DNI Status	1.010 (0.299, 1.722)	0.005	1.090 (0.500, 1.680)	< 0.001	-0.110 (-0.679, 0.459)	0.704
Unfavorable discharge status (hospice, acute care, or nursing facility)	2.390 (0.339, 4.441)	0.022	1.785 (0.690, 2.879)	0.001	0.283 (-0.354, 0.921)	0.384
Baseline mRS	-0.079 (- 0.872, 0.714)	0.845	-0.231 (- 0.833, 0.372)	0.453	0.299 (-0.180, 0.778)	0.222
Admission mRS	1.775 (0.939, 2.611)	<0.001	0.844 (0.317, 1.371)	0.002	-0.009 (-0.443, 0.424)	0.966
ICH score	1.345 (0.756, 1.934)	<0.001	0.682 (0.211, 1.154)	0.005	-0.260 (-0.680, 0.161)	0.227


354

 1.934)
 Image: Constraint of the second s

(Group D excluded as healthy reference group). Odds ratios, 95% CI and p-values included after 355 356 controlling for covariates.


\*Note that the Group A was not included in the regression due to complete separation, where Group A 357

only consisted of cases in Table 1. 358



**Group A** 


359



**Group B** 

360

Stress-induced hyperglycemia in primary ICH. Gilotra K et al. 2024.



361

Figures 3A-3C: Multivariate ordinal and logistic regression with odds ratios and 95% CI for Group A patients (Figure 3A: SIH), Group B patients (Figure 3B: DM and hyperglycemia on admission) and Group C patients (Figure 3C: normoglycemia on admission and pre-existing DM). All regression models adjusted for history of HTN, HLD, CAD, CHF, obesity, prior ICH, AF, malignancy, anticoagulation and antiplatelet therapy. Odds ratio, OR=1 is plotted as the vertical dashed line with any OR > 1 being considered as an unfavorable outcome.